Back in June, the FDA extended its deadline for decision for Novartis’ multiple sclerosis prospect ofatumumab by three months. But it turns out that the agency was not needed for so long. U.S. regulators on Thursday removed the drug, which will go by the name Kesimpta, into relapsing forms of …
Read More »Novartis gets green light to challenge Roche, Sanofi with delayed MS with Kesimpta
